Skip to main content
Premium Trial:

Request an Annual Quote

Biotage Announces Employee Stock Option, Plans to Issue New Shares

NEW YORK, Feb. 22 (GenomeWeb News) - Biotage directors have authorized 549,600 employee stock options for allotment under a global option program for employees in the Biotage group - Biotage AB Global Share Option Plan 2005, the company said today.

 

Members of the group management will receive a maximum of 45,000 options each, members of the junior management will receive a maximum of 10,000 options each, other members of management and key employees will receive a maximum of 2,000 each, and other employees will receive a maximum of 400 each. The CEO and president has not been allotted any options.

 

Each option entitles the holder to buy one ordinary share at a price of SEK 11.83 ($1.50). The options have an exercise period of seven years. The holder must be an employee at the time of exercise.


The company will issue up to 640,000 warrants to subscribe for new shares to cover the employee stock option program.

 

The issue was authorized by shareholders on April 27. 

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.